YI.US

Drug seller 111 Inc. (YI.US) said on Wednesday its revenue fell 6.4% year-on-year to 3.2 billion yuan ($450 million) in the second quarter, as revenue for its core business of selling drugs to pharmacies and medical institutions fell by 6.2%. Its much smaller business of selling drugs directly to consumers also fell 9.6% for the quarter year-on-year.

The company’s operating costs and expenses fell by a similar 6.3% to 3.2 billion yuan from 3.4 billion yuan in the year-ago period. As a result, 111 Inc. reported positive income from operations of $100,000 for the quarter. But its net loss widened to 19.5 million yuan from 14 million yuan a year earlier.

The company’s shares fell 6.2% on Wednesday after the report’s publication. The stock is down 40% over the last six months.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Goodbaby makes strollers

Investors left crying as U.S. tariffs hit Goodbaby

The world’s leading producer of baby strollers and car seats is getting socked by a double whammy of U.S. tariffs and China’s baby bust Key Takeaways: Goodbaby reported its revenue…
Seeking a profile boost, Boxihe pivots to Hong Kong IPO

Seeking a profile boost, Boxihe pivots to Hong Kong IPO

The maker of high-performance outdoor clothing is betting on rising demand for its Pelliot apparel range in China’s still relatively untapped market   Key Takeaways: The company’s pre-IPO backers include Tencent…
Damai sells concert tickets

Damai rides China’s offline leisure boom to bumper profits

The company’s dominance in live entertainment ticketing and IP franchises has turbocharged its revenue, despite persistent consumer complaints and monopolistic behavior Key Takeaways: Damai’s profit rose around 50% in the…